Roche to present important new data reflecting broad cancer pipeline at ASCO

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that important new data from clinical trials of several investigational and approved cancer medicines will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 to June 4, 2013, in Chicago. At the meeting, Roche medicines will be highlighted in more than 275 abstracts, of which around one third were chosen for oral presentations. The collection of data at ASCO represents Roche’s breadth of research and includes:

• Next-generation biologics, such as glycoengineered antibodies and antibody-drug conjugates
• Immunotherapies designed to work with the body’s immune system
• Medicines designed to interfere with cancer cell growth and survival mechanisms
• Ongoing efforts to map the precise characteristics of tumour cells helping to determine which patients may respond to an experimental medicine

“We need treatments that attack cancer cells in a variety of ways to continue to make a difference to the lives of people facing this disease,” said Hal Barron M.D., chief medical officer and head, Global Product Development. “From harnessing a person’s immune system to delivering chemotherapy directly to a cancer cell, we believe the new data from our pipeline presented at ASCO have the potential to markedly change how cancer is treated.”

Full session details of the 2013 Annual Meeting can be found through the ASCO iPlanner: https://iplanner.asco.org/am2013